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associated with specific conditions.
Study designs and other criteria for inclusion in the review
It was unclear whether a systematic review of the literature was undertaken to identify primary studies. No information on the design of the primary sources was provided. All-cause mortality was obtained from age-specific actuarial life tables.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Eleven primary studies appear to have provided the model inputs.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
Transition probabilities were not reported.
The all-cause mortality rate was 0.004443.
The rate of mortality due to primary THA was 0.006 (range: 0.001 -0.015).
The rate of mortality due to revision THA was 0.012 (range: 0.003 -0.026).
The utility value was: 0.5 (range: 0.32 to 0.85) for osteoarthritis before primary THA, 0.92 (range: 0.66 to 0.98) for successful primary THA, and 0.80 (range: 0.6 to 0.95) for successful revision THA.
Measure of benefits used in the economic analysis
The summary benefit measure was the expected number of quality-adjusted life-years (QALYs). These were obtained by combining utility values and expected survival in a modelling approach. A discount rate of 3% was applied to future benefits.
Direct costs
The perspective of the cost analysis was not explicitly stated, although only the direct medical costs were considered. The costs included were those associated with primary or revision THA and the use of bearings. The unit costs were not presented separately from the resource quantities and were reported as macro categories. The costs were derived from outpatient billing records and from an activity-based hospital cost accounting system. The costs of alternative bearings were based on published studies. The source of the resource use data was not explicitly stated. Discounting was relevant, as long-term costs were estimated, and an annual rate of 3% was applied. The price year was not reported.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not included.
Currency

US dollars ($).
Sensitivity analysis
Multi-way sensitivity analyses were carried out to assess the impact of changes in the age of the patients, implant costs and the probability of implant failure at 20 years on the relative cost-effectiveness of alternative versus conventional bearings. The analyses were based on threshold values for alternative bearings being cost-saving or cost-effective.
Estimated benefits used in the economic analysis
The total QALYs were not reported.
Cost results
The expected costs were not reported.
Synthesis of costs and benefits
The costs and benefits were combined using a cost-utility ratio. However, these ratios were not reported as the analysis used an approach based on thresholds. Two thresholds were chosen for parameter values. One threshold considered the alternative bearing surfaces to be cost-saving in comparison with conventional bearings, while the other threshold assumed a willingness-to-pay of $50,000 per QALY.
The threshold analysis revealed that, in a population of 50-year-old patients, the use of an alternative bearing with an incremental cost of $2,000 (which represents the average incremental cost associated with a hard-on-hard bearing couple) would be cost-saving over the individual's lifetime if it were associated with a reduction in the 20-year implant failure rate of at least a 18.7% in comparison with the failure rate for a conventional bearing. The same implant in the same population would have to result in a 3.8% reduction in the 20-year implant failure rate in order to be considered cost-effective (less than $50,000 per QALY).
In a population of patients over the age of 63 years, the same implant would be associated with higher lifetime costs than a conventional bearing, regardless of the presumed reduction in the revision rate. In addition, it would have to result in an 11.3% reduction in the 20-year implant failure rate in order to be considered cost-effective.
An alternative bearing with an incremental cost of $2,000 in a population of patients over the age of 70 years would need to be associated with at least a 45.5% reduction in the 20-year implant failure rate in order to be considered costeffective.
